A. Karnofsky performance status B. Time from diagnosis to treatment C. Lactate dehydrogenase level more than 1.5 times of the upper limit of normal (ULN) D. Neutrophils higher than ULN

A. Nivolumab B. Sunitinib C. Temsirolimus D. Sorafenib

A. Overall survival benefit was seen with nivolumab versus everolimus. B. Adverse events were higher with nivolumab compared with everolimus. C. Nivolumab only provided benefit in patients with favorable Memorial Sloan Kettering Cancer Center criteria prognostic factors. D. Nivolumab was not associated with improved health-related quality of life.

A. PD-1 and CTLA-4 provide non-complementary roles in regulating adaptive immunity. B. The response rate seen in the phase I trial of nivolumab and ipilimumab was 10%. C. An overall response rate of 52% was seen in the phase I trial of nivolumab plus sunitinib. D. In the phase I trial of nivolumab plus pazopanib, liver toxicity was not identified

A. Several prophylactic treatments are available for treating patients with diarrhea B. Grade 3 and 4 diarrhea is higher with CTLA-4 inhibitors versus PD-L1 inhibitors. C. Steroid treatment is not recommended. D. Patients with checkpoint-associated diarrhea do not require monitoring.

A. Thyroid function monitoring is required before each dose of ipilimumab or the combination of ipilimumab and nivolumab. B. Monitoring clinical symptoms is sufficient for the early detection of endocrinopathies. C. Monitoring for endocrinopathies is only indicated for high risk patients. D. Patients should only be monitored for hypothyroidism.

A. Axitinib B. Everolimus C. Nivolumab D. Ipilimumab